We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+7.37%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.91B
AUM Growth
+$452M
Cap. Flow
+$173M
Cap. Flow %
2.51%
Top 10 Hldgs %
46.12%
Holding
78
New
10
Increased
15
Reduced
10
Closed
10

Top Buys

Rank Stock Value
1
GERN icon
Geron
GERN
+$201M
2
SYK icon
Stryker
SYK
+$137M
3
ORKA
Oruka Therapeutics
ORKA
+$60.3M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$19.9M
5
DYN icon
Dyne Therapeutics
DYN
+$17.2M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$90.1M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$65.8M
3
AXSM icon
Axsome Therapeutics
AXSM
+$38.8M
4
VCEL icon
Vericel Corp
VCEL
+$36.8M
5
FULC icon
Fulcrum Therapeutics
FULC
+$36.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARS icon
26
Tarsus Pharmaceuticals
TARS
$2.84B
$112M 1.62%
3,412,486
– –
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$2.55B
$109M 1.58%
1,968,002
-1,291,925
-40% -$65.8M
SYRE icon
28
Spyre Therapeutics
SYRE
$9.25B
$95.8M 1.39%
3,258,360
– –
CRGX
29
DELISTED
CARGO Therapeutics
CRGX
$75.6M 1.09%
4,098,955
+20,833
+0.5% +$373K
ARVN icon
30
Arvinas
ARVN
$572M
$68.5M 0.99%
2,782,329
-185,568
-6% -$4.85M
STOK icon
31
Stoke Therapeutics
STOK
$2.11B
$57.2M 0.83%
4,652,285
+427,447
+10% +$6.05M
ETNB
32
DELISTED
89bio
ETNB
$54.6M 0.79%
7,378,548
– –
CGON icon
33
CG Oncology
CGON
$6.66B
$50.7M 0.73%
1,344,074
– –
GKOS icon
34
Glaukos
GKOS
$10.6B
$50.3M 0.73%
386,291
– –
URGN icon
35
UroGen Pharma
URGN
$2.29B
$48.1M 0.7%
3,787,347
+230,000
+6% +$3.41M
NGNE icon
36
Neurogene
NGNE
$712M
$47.6M 0.69%
1,135,256
+64,691
+6% +$2.51M
ORKA
37
Oruka Therapeutics
ORKA
$5.96B
$45.4M 0.66%
1,850,648
+1,733,981
+1,486% +$60.3M
OBIO icon
38
Orchestra BioMed
OBIO
$254M
$42.2M 0.61%
8,206,159
+2,585,519
+46% +$16.9M
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$40.4M 0.58%
5,591,700
+111,123
+2% +$1.02M
TSHA icon
40
Taysha Gene Therapies
TSHA
$1.89B
$30M 0.43%
14,946,420
-3,853,879
-20% -$8.46M
CGEM icon
41
Cullinan Oncology
CGEM
$1.14B
$28.6M 0.41%
1,705,960
+653,330
+62% +$11.6M
TEM
42
Tempus AI
TEM
$9.39B
$22.6M 0.33%
400,000
– –
GHRS icon
43
GH Research
GHRS
$2.08B
$22.3M 0.32%
3,327,129
– –
LENZ
44
LENZ Therapeutics
LENZ
$168M
$20.5M 0.3%
863,389
– –
EPIX
45
DELISTED
ESSA Pharma
EPIX
$19.8M 0.29%
3,261,496
+962,834
+42% +$5.29M
TRML
46
DELISTED
Tourmaline Bio
TRML
$19.1M 0.28%
741,656
– –
DNTH icon
47
Dianthus Therapeutics
DNTH
$6.09B
$18.3M 0.26%
666,667
– –
ROIV icon
48
Roivant Sciences
ROIV
$26.2B
$16.8M 0.24%
1,454,273
– –
BIOA
49
BioAge Labs
BIOA
$538M
$16.4M 0.24%
+786,353
New +$15.8M
REPL icon
50
Replimune Group
REPL
$1.01B
$12.4M 0.18%
1,133,787
– –
1
2
3 4

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q3 2024 Portfolio in Review

As of Q3 2024, RTW Investments held 78 positions worth $6.91B, up 7% from $6.46B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

RTW Investments's Q3 2024 filing shows 10 new, 15 increased, 10 reduced and 10 closed positions. Its largest new stake was Geron: 44,111,916 shares worth $200M. The largest sale was Intuitive Surgical, an estimated $90.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q3 2024 buy was Geron: 44,111,916 shares worth $200M.
  • RTW Investments added most to Oruka Therapeutics in Q3 2024, an estimated $60.3M increase.
  • RTW Investments's biggest Q3 2024 reduction was Ultragenyx Pharmaceutical, cutting an estimated $65.8M.
  • RTW Investments fully exited Intuitive Surgical in Q3 2024, selling an estimated $90.1M.
  • RTW Investments's ten largest holdings make up 46% of its $6.91B portfolio in Q3 2024.
  • RTW Investments opened 10 new positions and closed 10 in Q3 2024.
  • RTW Investments's portfolio value rose 7% quarter-over-quarter to $6.91B.

Based on RTW Investments's 13F filing for Q3 2024, filed 14 Nov 2024.